Clinical Trials Browser

etirinotecan pegol × Clear all

NCT02915744 2023-04-14

ATTAIN

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT05158491 2022-01-05

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

Phase 1/2 Unknown

Small Cell Lung Carcinoma

NCT00856375 2021-07-12

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Phase 2 Completed

83 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT01457118 2021-07-12

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Phase 2 Completed

27 enrolled 18 charts

Other solid neoplasm

Malignant Solid Tumor

NCT01876446 2020-03-17

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

38 enrolled 16 charts

Small Cell Lung Carcinoma

NCT00802945 2018-07-09

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Phase 2 Completed

70 enrolled 15 charts

Breast Neoplasms, Neoplasms

NCT01976143 2016-12-22

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

Phase 1 Completed

Other solid neoplasm

Advanced Cancer

NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Phase 2 Completed

20 enrolled 10 charts

Astrocytoma, Glioblastoma, Oligodendroglioma